Indirubin, an isomer of indigo, is a reported inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) as well as an agonist of the aryl hydrocarbon receptor (AhR). Indirubin is the active ingredient of a traditional Chinese medicinal recipe used against chronic myelocytic leukemia. Numerous indirubin analogs have been synthesized to optimize this promising kinase inhibitor scaffold. We report here on the cellular effects of 7-bromoindirubin-3 0 -oxime (7BIO). In contrast to its 5-bromo-and 6-bromo-isomers, and to indirubin-3 0 -oxime, 7BIO has only a marginal inhibitory activity towards CDKs and GSK-3. Unexpectedly, 7BIO triggers a rapid cell death process distinct from apoptosis. 7-Bromoindirubin-3 0 -oxime induces the appearance of large pycnotic nuclei, without classical features of apoptosis such as chromatin condensation and nuclear fragmentation. 7-Bromoindirubin-3 0 -oxime-induced cell death is not accompanied by cytochrome c release neither by any measurable effector caspase activation. Furthermore, the death process is not altered either by the presence of Q-VD-OPh, a broad-spectrum caspase inhibitor, or the overexpression of Bcl-2 and Bcl-XL proteins. Neither AhR nor p53 is required during 7BIO-induced cell death. Thus, in contrast to previously described indirubins, 7BIO triggers the activation of non-apoptotic cell death, possibly through necroptosis or autophagy. Although their molecular targets remain to be identified, 7-substituted indirubins may constitute a new class of potential antitumor compounds that would retain their activity in cells refractory to apoptosis.
Introduction
In man, 518 þ protein kinases and 80 þ protein phosphatases control the phosphorylation of enzymes and structural proteins. Phosphorylation/dephosphorylation constitutes one of the most common yet complex post-translational cellular regulatory mechanism. Abnormal phosphorylation on specific proteins is observed in essentially all pathologies and this has stimulated an extraordinary interest in small molecular weight inhibitors of kinases and phosphatases. Protein kinases now constitute the second class of targets (after G-protein-coupled receptors) used in the drug screening efforts of the pharmaceutical industry (reviews in Cohen, 2002; Fischer, 2004; Weinmann and Metternich, 2005) . These efforts have received considerable support from the remarkable success story of Gleevec, one of the first commercial kinase inhibitors. Currently, 55 kinase inhibitors are under clinical evaluation against diseases such as cancers, inflammation, diabetes, neurodegeneration, etc.
Cyclin-dependent kinases (CDKs) play essential functions all along the cell cycle and there are multiple examples of dysfunctions of CDKs and their regulators in cancer (Vermeulen et al., 2003) . Furthermore, CDKs are involved in various neurodegenerative diseases such as Alzheimer's, Parkinson's and Nieman-Pick's diseases, ischemia and traumatic brain injury. A few academic groups, and most pharmaceutical companies, have thus invested in the search for pharmacological inhibitors of CDKs (reviews in Knockaert et al., 2002; Fischer et al., 2003; Benson et al., 2005; Fischer and GianellaBorradori, 2005) . Optimization of such inhibitors has been efficiently assisted by their co-crystallization with CDK2 (Noble et al., 2004) , CDK5 (Mapelli et al., 2005) and CDK6 (Lu et al., 2005) .
The bis-indole alkaloid indirubin and its analogs (collectively referred to as indirubins) were among some of the early CDK inhibitors to be discovered (Hoessel et al., 1999) . The red/purple indirubin is an isomer of the blue indigo. Both are derived from the spontaneous, non-enzymatic dimerization of isatin and indoxyl, two precursors found either free or conjugated to carbohydrates in natural sources. Indirubins can indeed be extracted from various indigo dye-producing plants (200 þ species) (Balfour-Paul, 1998) . They are also present in the historic 'Tyrean purple' dye extracted from various Muricidae mollusks (15 þ species) review in Cooksey, 2001) . They are also extracted from various wild-type and recombinant bacteria (Guengerich et al., 2004; Wu et al., 2005 and references therein). Finally, indirubin and indigo are occasionally present in human urine (Adachi et al., 2001 and references therein). Interestingly, indirubin is the active ingredient of a traditional Chinese medicine recipe, Danggui Longhui Wan, used to treat various diseases including chronic myelocytic leukemia (review in Xiao et al., 2002) . Besides CDKs, indirubins were found to target glycogen synthase kinase-3 (GSK-3) (Leclerc et al., 2001) , glycogen phosphorylase b (Kosmopoulou et al., 2004) and the aryl hydrocarbon receptor (AhR), also known as the dioxin receptor (Adachi et al., 2001; Kawanishi et al., 2003) . Aryl hydrocarbon receptor mediates the effects of many xenobiotics such as dioxin and indole-containing compounds (review in Denison and Nagy, 2003) . Upon binding to xenobiotic-responsive element, activated AhR induces the transcription of numerous genes, including cytochrome P450 CYP1A1, p27 kip1 , myristoyltransferase, etc. (review in Elferink, 2003) . Evidence suggests that the antiproliferative effects of indirubins derive from their ability to inhibit CDKs (Damiens et al., 2001; Marko et al., 2001) . However, interaction with AhR and the subsequent induction of p27 kip1 contributes to a marked arrest in G1 (Knockaert et al., 2004) . Finally it has been recently shown that some indirubins prevent the phosphorylation and subsequent activation of the transcription factor signal transducers and activators of transcription (STAT3), leading to a downregulation of survival factors such as survivin and Mcl-1, and subsequent induction of cell death (Nam et al., 2005) .
In this article, we report on a new subfamily of indirubins, substituted on position 7. Unexpectedly, despite weak or insignificant inhibitory activity on various classical kinase targets of indirubins, 7-bromoindirubin-3 0 -oxime potently induces a rapid cell death distinct from classical apoptosis. The possible mechanisms of action of 7-substituted indirubins and their potential as antitumor agents will be discussed.
Results

Different bromoindirubins display different selectivities for kinases
In a previous study, we observed that a bromine substitution of indirubins on position 6 led to compounds with increased selectivity towards GSK-3 Polychronopoulos et al., 2004) . We further extended this work by synthesizing and comparing indirubin-3 0 -oxime (IO) and 5-bromo-(5BIO), 6-bromo-(6BIO) or 7-bromoindirubin-3 0 -oxime (7BIO) ( Table 1) . Surprisingly, compared to IO, 5BIO and 6BIO, 7BIO displayed very weak inhibitory activity towards our routine screening kinase targets, GSK-3, CDK1/cyclin B, CDK5/p25. Replacement of the bromine substituent by chlorine (7-chloroindirubin-3 0 -oxime (7CIO)) or iodine (7-iodoindirubin-3 0 -oxime (7IIO)) did not improve the potency of the 7-halogeno-indirubin-3 0 oximes, whereas substitution with fluorine (7-fluoroindirubin-3 0 -oxime (7FIO)) enhanced the kinase inhibitory potency (Table 1) . Finally, substitution of 7BIO on N1 with a methyl group Abbreviations: CDK, cyclin-dependent kinase; GSK-3, glycogen synthase kinase-3. A series of indirubin analogues were tested at various concentrations in the kinase assays, as described in the Materials and methods section. IC 50 values were calculated from the dose-response curves and are reported in mM.
Antitumor activity of 7-bromoindirubin-3 0 -oxime J Ribas et al (1-methyl-7-bromoindirubin-3 0 -oxime (Me7BIO)) led to a completely inactive compound, as observed previously with Me6BIO .
We next investigated the selectivity of IO, 5BIO, 6BIO and 7BIO in the 85 kinase ProQinase selectivity panel (Table 2 ) (in contrast to the above-mentioned kinase assays performed at a final 15 mM ATP concentration, the ProQinase assays are run in the absence of cold ATP. As indirubins act by competing with ATP binding, the IC 50 values are dependent on the assay ATP concentration, therefore the values of Tables 1 and 2 cannot be compared directly). This approach first revealed that Aurora A-C, FMS-like tyrosine kinase 3 (FLT3), RET constitute new targets of IO, 5BIO and 6BIO. Vascular endothelial growth factor receptor (VEGF-R) had been previously described as a target for indirubins (Jautelat et al., 2005) . The selectivity panel also revealed that, compared to the three other indirubins, 7BIO is a poor kinase inhibitor. Only one kinase, FLT3, was inhibited by 7BIO with an IC 50 below 1 mM (Table 2 ) (15 kinases for IO, 11 for 5BIO, 19 for 6BIO). 7-Br-, 7Cl-and 7I-substituted indirubin-3 0 -oximes showed a significant inhibitory activity towards Aurora C, a modest activity on Aurora B and little activity, if any, on Aurora A (data not shown), whereas 7FIO appeared to be equipotent on the three Aurora forms. Unexpectedly, Me7BIO was found to be rather active on Aurora C, but completely inactive on Aurora A and B (data not shown). FMS-like tyrosine kinase 3 was found to be sensitive to all eight indirubins tested including Me7BIO. The effects of indirubins on Aurora kinases and FLT3 will be reported in detail elsewhere.
Induction of cell death by indirubins
We next compared the four indirubins for their ability to induce cell death in neuroblastoma SH-SY5Y cells as measured with an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 2H-tetrazolium   KINASE  IO  5BIO 6BIO 7BIO  ABL1  >100 >100  3.4  >100  AKT1  >100 >100  >100  >100  AKT2  >100 >100  >100  >100  AKT3 n. n.t. n.t. >100 >100 PKC-alpha >100 >100 >100 >100 PKC-beta1 >100 >100 >100 >100 PKC-beta2 >100 >100 >100 >100 PKC-delta >100 >100 >100 65 PKC-epsilon >100 >100 >100 >100 PKC-eta >100 >100 >100 >100 PKC-gamma >100 >100 >100 >100 PKC-iota >100 >100 >100 >100 PKC-mu >100 >100 >100 >100 PKC-theta >100 >100 86 >100 PKC-zeta >100 >100 >100 96 PLK1 >100 >100 >100 >100 PRK1 >100 >100 70 >100 RET 0.18 2.2 0.05 22 S6K 82 >100 6.1 >100 IC 50 value (µM) < 0.1 0.1 -1 1 -10 10 -100 > 100 .
(MTS) reduction assay ( Figure 1a ). As MTS reduction is occasionally observed under conditions different from cell death, we used an independent cell death assay, the lactate dehydrogenase (LDH) release assay ( Figure 1b ). Dose-response curves showed that 7BIO is the most potent compound in terms of concentration required to reduce cell survival (MTS reduction) (Figure 1a ) or to induce cell death (LDH release) (Figure 1b) . However, 7BIO's efficacy was sensitive to the concentration of serum, suggesting that it binds to serum proteins (data not shown). Different halogens were introduced in position 7 of indirubin-3 0 -oxime ( Figure 2 , Table 1 ). 7-Fluoroindirubin-3 0 -oxime was poorly active on cells compared to the equipotent 7BIO and 7CIO. 7-Iodoindirubin-3 0 -oxime was the most potent compound (Figure 2a) . These results did not correlate with those obtained in the in vitro kinase assays (Table 1) . Methylation on N1, leading to Me7BIO, totally abolished the cell death-inducing ability of 7BIO ( Figure 2b ). As 7BIO was a poor inhibitor of kinases and yet a potent cell death inducer, we decided to investigate the effects of this compound in more detail.
To ascertain that the induction of cell death by 7BIO was not a specific property of SH-SY5Y cells, we also used the breast cancer cell line MDA-MB-231 (Figure 3) . A 48-h exposure to 7BIO induced a dose-dependent inhibition of cell proliferation as evidenced by direct counting. This effect was poorly if at all reversible by removal of 7BIO (Figure 3a) . We next analysed the effects of 7BIO on cell cycle distribution (Figure 3b) . A tendency towards accumulation in G2/M and reduction of G0/G1 was observed, as described previously for other indirubins (Hoessel et al., 1999; Damiens et al., 2001; Marko et al., 2001 ).
Induction of cell death by 7-bromoindirubin-3
0 -oxime does not require aryl hydrocarbon receptor Indirubins interact with AhR (Adachi et al., 2001) . This interaction may contribute to the cellular effects of indirubins (Knockaert et al., 2004) . However, SH-SY5Y 0 oxime (a) and 1-methyl-7-bromoindirubin-3 0 oxime (b) on the survival of SH-SY5Y cells. SH-SY5Y cells were exposed for 48 h to increasing concentrations of 7-chloro-, 7-iodo-, 7-bromo-, or 7-fluoroindirubin-3 0 oxime (7CIO, 7IIO, 7BIO, 7FIO, respectively) (a) or 1-methyl-7-bromoindirubin-3 0 oxime or 7BIO (b). Cell survival was estimated by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reduction assay and is expressed in % of survival in untreated cells. Average7s.e. of three determinations.
Antitumor activity of 7-bromoindirubin-3 0 -oxime J Ribas et al cells seem to be devoid of AhR (unpublished data). To evaluate the contribution of AhR to the cell death effects of 7BIO, we made use of two hepatoma cell lines, 5L (AhR þ / þ ) and its AhR-deficient subclone, BP8 (AhR À/À) (Weiss et al., 1996; Kolluri et al., 1999; Knockaert et al., 2004) . We first confirmed that, like 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (dioxin), both 7BIO and Me7BIO potently enhance the AhRdependent expression of the CDK inhibitory protein p27
Kip1 (Figure 4a ), as reported previously for IO and 6BIO and their methylated counterparts, 1-methylindirubin-3 0 -oxime (MeIO) and Me6BIO (Knockaert et al., 2004) . No correlation is thus observed between induction of p27 Kip1 expression ( Figure 4a ) and induction of cell death ( Figure 2b ). We next analysed the effects of 7BIO and Me7BIO on cell cycle distribution of AhRÀ/À and AhR þ / þ cells. As reported for other indirubins, both 7BIO and Me7BIO induced a striking AhR-dependent accumulation in G0/G1 (Figure 4b ). Finally, cell death induction was estimated in both cell lines following exposure to increased 7BIO concentrations. The dose-response curves were essentially the same (Figure 4c ). Altogether these results show that AhR is not involved in the cell death inducing properties of 7BIO.
7-Bromoindirubin-3
0 -oxime-induced cell death involves neither p53 nor p21
Cip1 nor STAT3 dephosphorylation We next investigated the involvement of p53 and p21 The cytotoxic effect of 7-bromoindirubin-3 0 -oxime (7BIO) is independent of aryl hydrocarbon receptor (AhR). (a) Hepatocyte AhRÀ/À (BP8) and AhR þ / þ (5L) cells were treated with 0.1 mM 2,3,7,8-tetrachlorodibenzo-p-dioxin, or 10 mM 7BIO or 1-methyl-7-bromoindirubin-3 0 -oxime (Me7BIO) for 24 h or with the vehicle dimethylsulfoxide (DMSO). The expression level of p27 KIP1 was determined by Western blotting using a specific antibody. Actin Western blotting was used as a loading control. (b) Both 7BIO and Me7BIO induce an AhR-dependent accumulation in G0/G1. 5L and BP8 cells were cultured in the absence (control) or presence of DMSO or 10 mM 7BIO or Me7BIO for 24 h, and the cell cycle phase distribution was determined by fluorescence-activated cell sorter analysis. (c) Both 5L and BP8 cell lines were exposed for 24 h to increasing concentrations of 7BIO or Me7BIO. Cell survival was estimated by the 3-[4,5] dimethylthiazol-2-5-diphenyltetrazolium bromide reduction assay and is expressed in % of survival in untreated cells. Average7s.e. of three determinations.
Antitumor activity of 7-bromoindirubin-3 0 -oxime J Ribas et al insignificant in cells treated with IO, 7BIO or Me7BIO (Figure 5a and b). As expected, analysis of p21 Cip1 expression under the same conditions showed a timedependent induction by 5BIO (Figure 5c ). p21 Cip1 expression occurred with some delay after p53 stabilization ( Figure 5b ). Indirubin-3 0 -oxime, 5BIO and 6BIO were roughly equipotent at inducing p21 Cip1 overexpression, whereas 7BIO and Me7BIO had negligible effects (Figure 5a ). Finally, we tested the effects of 7BIO on wild-type HCT-116 and a HCT-116 subclone deprived of p53 (Figure 5e ). The dose-response curves were essentially the same. Altogether, these data suggest that 7BIO-induced cell death does not induce p53 nor require its contribution.
Tyrosine phosphorylation and subsequent activation of the transcription factor STAT3 were recently shown to be inhibited by some indirubins, leading to the downregulation of survival factors and subsequent induction of cell death (Nam et al., 2005) . To examine whether this mechanism is involved in the action of 7BIO, we investigated the effect from IO, 5BIO, 6BIO and 7BIO on the level of tyrosine 705-phosphorylated STAT3 in MDA-MB-231 cells ( 0 -oxime (IO), 5-bromoindirubin-3 0 -oxime (5BIO), 6-bromoindirubin-3 0 -oxime (6BIO), 7-bromoindirubin-3 0 -oxime (7BIO) or 1-methyl-7-bromoindirubin-3 0 -oxime (Me7BIO), 1 mM staurosporine or 12.5 mM etoposide for 12 h. Cells were then harvested and proteins were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting using antibodies directed against p53, p21 CIP1 or actin (used as internal loading marker). (b-d) SH-SY5Y cells were treated with 12.5 mM 5BIO or 7BIO or 12.5 mM etoposide for various times. Cells were then harvested and proteins were resolved by SDS-PAGE followed by Western blotting using antibodies directed against p53 (b), p21
CIP1 (c) or actin (d). (e) Wild-type ( ) and p53-deprived (J)
HCT-116 cells were exposed for 48 h to increasing concentrations of 7BIO or Me7BIO. Cell survival was estimated by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reduction assay and is expressed in % of survival in untreated cells. Average7s.e. of three determinations. 0 -oxime (5BIO), 6-bromoindirubin-3 0 -oxime (6BIO), 7-bromoindirubin-3 0 -oxime (7BIO), or the dimethylsulfoxide carrier for 4 h, or with 100 ng/ml of interferon-a for 5 min. Cellular proteins were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis followed by Western blotting using antibodies directed total STAT3 and tyrosine-phosphorylated STAT3. Western blotting with antiactin antibodies provided a loading marker.
Antitumor activity of 7-bromoindirubin-3 0 -oxime J Ribas et al low compared to the level reached by stimulation with IFNa, yet it is downregulated by IO, 5BIO and 6BIO but not by 7BIO. This suggests that the mechanism of action of 7BIO is not primarily due to an inactivation of tyrosine-phosphorylated STAT3.
Induction of cell death by 7-bromoindirubin-3 0 -oxime is much faster than by other indirubins A time course of SH-SY5Y cell death induction was next performed following exposure to 25 mM IO, 5BIO, 6BIO, 7BIO or Me7BIO (Figure 7) . Although 5BIO and 6BIO required 36-48 h to induce 70% cell death, this level was reached by 12 h with 7BIO. Almost complete cell death was obtained with 7BIO within 24 h (Figure 7 ). This much faster kinetics suggests that a different mechanism of cell death is occurring in the case of 7BIO compared to the other indirubins. Alternatively, a subpopulation of cells may respond to 5BIO and 6BIO as they do to 7BIO, whereas the vast majority undergoes apoptosis.
7-Bromoindirubin-3
0 -oxime induces non-apoptotic cell death To investigate the mechanism of action of 7BIO, we first examined, under a fluorescence microscope, SH-SY5Y cells exposed to different indirubins following Bisbenzimide and propidium iodide (PI) staining (Figure 8) . First of all, no PI staining was observed in control cells and in Me7BIO-treated cells (Figure 8a and f) , confirming the absence of cell death. Indirubin-3 0 -oxime, 5BIO and 6BIO all triggered nuclear fragmentation typical of apoptosis, accompanied by secondary necrosis (Figure 8b-d) . These figures were never observed in 7BIO-treated cells that, in contrast, displayed numerous large, unfragmented pycnotic nuclei (Figure 8e ). Such figures were observed only occasionally with 5BIO and 6BIO (Figure 8c and d) . These morphological results suggest that 7BIO triggers an atypical cell death different from apoptosis.
To challenge this possibility, the activity of caspases was assayed in SH-SY5Y cells exposed to various concentrations of different indirubins (Figure 9 ). 5-bromoindirubin-3 0 -oxime and 6BIO and IO to a lesser extent, triggered a dose- (Figure 9a ) and time- (Figure 9b ) dependent activation of caspase. In sharp contrast, neither 7BIO nor Me7BIO induced any activation of caspases, which remained at the level of control, untreated cells. Furthermore, Q-VD-OPh, a general caspase inhibitor (Caserta et al., 2003) , had no effect on cell death induced by 7BIO (Figure 10 ), whereas it reduced the level of cell death induced by 5BIO and 6BIO, and IO, to a lesser extent (Figure 10a ). The time course of 7BIO-induced cell death was unaffected by Q-VD-OPh (Figure 10b) .
Moreover, 7BIO triggered negligible release of cytochrome c from mitochondria ( Figure 11 ). Under the same conditions IO, 5BIO and 6BIO induced the release of cytochrome c to levels similar to those reached by standard apoptosis-inducing reagents like staurosporine (STS) and etoposide. We next examined DNA laddering as a reflection of apoptotic cell death. The laddering caused by R-Roscovitine was consistent with the reported ability of this compound to induce apoptosis (Ribas and Boix, 2004) . 5-Bromoindirubin-3 0 -oxime and to a lesser extent 6BIO, also induced internuclesosomal fragmentation, whose intensity was proportional to the amount of apoptotic cells in the culture (see Bisbenzimide/PI staining in Figure 8 ). In 7BIO-treated cells, no ladder was observed; however, most cells were dead. In Me7BIO, IO and dimethylsulfoxide (DMSO) treatments, cell death induction was negligible and no laddering was detected.
Altogether these results show that 7BIO-induced cell death does not induce cytochrome c release and does not trigger nor require the activation of caspases, in sharp contrast with cell death induced by IO, 5BIO and 6BIO. Thus 7BIO appears to induce a cell death pathway which differs from the apoptosis induced by IO, 5BIO and 6BIO.
0 -oxime-induced cell death is not inhibited by cellular mechanisms able to protect cells from apoptosis To further explore the cell death process triggered by 7BIO, we wondered whether proved mechanisms of resistance to apoptosis were able to protect cells from 7BIO's effects. SH-SY5Y cells can be differentiated in cell culture by retinoic acid (RA) and this differentiation prevents apoptosis triggered by CDK inhibitors like olomoucine or roscovitine (Ribas and Boix, 2004) . Similarly, differentiation renders SH-SY5Y cells refractory to STS. As shown in Figure 12 , differentiation had negligible effect on the rates of 7BIO-induced cell death. 0 -oxime (6BIO), 7BIO or 1-methyl-7-bromoindirubin-3 0 -oxime (Me7BIO) for 6, 12, 24, 36 or 48 h. Cell survival was assessed by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium procedure. Every point is the mean7s.e. of two independent experiments with at least three independent measurements per experiment.
Antitumor activity of 7-bromoindirubin-3 0 -oxime J Ribas et al Bcl-2 and Bcl-XL proteins are known for their antiapoptotic effects. In addition, their cytoprotective effects have been found to extend beyond apoptosis (Kane et al., 1995) . We previously described that Bcl-2 and Bcl-XL overexpression protects SH-SY5Y cells from apoptosis triggered by STS (Yuste et al., 2002) . As reported, Bcl-XL surpassed Bcl-2 at inhibiting STS-induced apoptosis (Figure 12b) . However, in a parallel time course experiment, neither Bcl-XL nor Bcl-2 overexpression provided any significant protection from 7BIO (Figure 12b ). Taken together, these results reinforce the action of 7BIO as an effective cell killer acting in an apoptosisindependent manner. 0 -oxime (IO), 5-bromoindirubin-3 0 -oxime (5BIO) and 6-bromoindirubin-3 0 -oxime (6BIO), 7-bromoindirubin-3 0 -oxime (7BIO) induces non-apoptotic cell death in SH-SY5Y cells. SH-SY5Y cells were exposed for 24 h to 0.1% dimethylsulfoxide (control) (a), 25 mM IO (b), 25 mM 5BIO (c), 10 mM 6BIO (d), 10 mM 7BIO (e) or 10 mM 1-methyl-7-bromoindirubin-3 0 -oxime (Me7BIO) (f). Following double staining of DNA with Bisbenzimide and propidium iodide, cells were examined by fluorescence microscopy. Thick arrows: apoptosis (nuclear fragmentation); thin arrows: secondary necrosis; arrowheads: pycnotic nuclei. Scale bar: 20 mm.
Antitumor activity of 7-bromoindirubin-3 0 -oxime J Ribas et al Non-apoptotic, caspase-independent cell death is a general characteristic of the death processes triggered by 7-bromoindirubin-3 0 -oxime To challenge the generality of the 7BIO effects, we tested 7BIO in two other human neuroblastoma-derived cell lines, IMR-5 and IMR-32, as well as two hematological tumors derived cell lines, Jurkat and HL-60. As shown in Figure 13 (left column), 7BIO induced cell death in the same range of concentrations characterized as lethal for SH-SY5Y, MDA-MB-231 (breast cancer) and HCT116 (colon cancer) cell types. The sensitivity of HL-60 cells (known to be deficient in p53 protein) to 7BIO is consistent with the lack of involvement of p53 as described above.
We further characterized the cell death process triggered by 7BIO in IMR-5, IMR-32, Jurkat and HL-60 cells. Bisbenzimide staining, fluorescence and electron microcopy characterizations demonstrated that nonapoptotic cell death was taking place as described in SH-SY5Y cells (data not shown). In addition, effector caspase activation was assessed at 24 h (Figure 13 , right). As expected, 5BIO triggered caspase activation. Compared with STS, 5BIO displayed reduced caspase activation, consistent with (1) the mixed type of cell death that 5BIO induces and (2) less synchronous kinetics of apoptosis induction. In contrast, DEVDase activity in 7BIO-treated cells fell consistently below the background displayed by control, untreated cells. In 0 -oxime (5BIO), 6-bromoindirubin-3 0 -oxime (6BIO), 7BIO or 1-methyl-7-bromoindirubin-3 0 -oxime for 48 h in the presence (black bars) or absence (white bars) of 10 mM Q-VDOPh, a broad spectrum inhibitor of caspases. Cell survival was assessed by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Every point is the mean7s.e. of four independent experiments with three independent measurements per experiment. In the control Q-VDOPh graph only two independent experiments were performed. (b) Time course of 7BIO-induced cell death in the absence (J) or presence ( ) of 10 mM Q-VD-OPh. Cells were exposed to 25 mM BIO at time 0 and cell survival was estimated at different time points by the MTS assay. Each point is the mean7s.e. of at least three independent experiments with three independent measurements per experiment.
Antitumor activity of 7-bromoindirubin-3 0 -oxime J Ribas et al conclusion, the non-apoptotic, caspase-independent type of cell death triggered by 7BIO appears to be an intrinsic property of the compound, independent of the cell model.
Discussion
Indirubins have been the object of many chemical modulations in order to improve their selectivity profile, kinase inhibitory efficacy and solubility. In particular, numerous modifications have been carried out on positions 3 0 , 5 0 , 6 0 on one indole ring and 5 or 6 on the other indole ring (Hoessel et al., 1999; Leclerc et al., 2001; Meijer et al., 2003; Merz et al., 2004; Polychronopoulos et al., 2004; Jautelat et al., 2005) . However, no modifications have ever been reported on position 7. One reason might be that substitution at this position almost annihilates inhibitory activity towards key targets of indirubins, CDKs and GSK-3. The fast and potent induction of cell death by 7BIO was totally unexpected, but provided the impetus to investigate 7-substituted indirubins further. Indirubins have been co-crystallized with CDK2 (Hoessel et al., 1999) , CDK2/cyclin A (Davies et al., 2001) , CDK5 (Mapelli et al., 2005) , PfPK5, the Plasmodium falciparum homolog of CDK1 (Holton et al., 2003) , GSK-3b (Bertrand et al., 2003; Meijer et al., 2003; Polychronopoulos et al., 2004) , and glycogen phosphorylase b (Kosmopoulou Indirubin-3 0 -oxime (IO), 5-bromoindirubin-3 0 -oxime (5BIO) and 6-bromoindirubin-3 0 -oxime (6BIO), but not 7-bromoindirubin-3 0 -oxime (7BIO), induce cytochrome c release and DNA laddering. (a) SH-SY5Y cells were treated with 12.5 mM IO, 5BIO, 6BIO, 7BIO or 1-methyl-7-bromoindirubin-3 0 -oxime (Me7BIO), 0.25 mM staurosporine or 12.5 mM etoposide for 10 h. Cells were then harvested and fractionated into a nuclear pellet and a cytoplasmic supernatant. The latter was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by Western blotting using an anticytochrome c antibody. The antibody crossreacts with an irrelevant protein used as an internal loading marker. (b) SH-SY5Y cells were treated with dimethylsulfoxide (0.25%), 25 mM IO, 5BIO, 6BIO, 7BIO or Me7BIO, or 25 mM (R)-roscovitine for 24 h. Cells were then harvested and internucleosomal DNA fragmentation was analysed by electrophoresis in 1.5% agarose gels. pcDNA3/Bcl-2 (J) and empty pcDNA3 ('), were treated with either STS (2 mM) or 7BIO (25 mM). Cell viability was analysed by the MTS procedure at 9 and 24 h of treatment. In the time course plots, every point is the mean7s.e. of three independent experiments with six independent values per experiment. (c) The Bcl-XL and Bcl-2 content of pcDNA3/Bcl-2 (1), pcDNA3/Bcl-XL (2) and pcDNA3/empty (3) transfected SH-SY5Y cells was assessed during the viability determination experiments by Western blotting. Tubulin content was used to control for protein load.
Antitumor activity of 7-bromoindirubin-3 0 -oxime J Ribas et al et al., 2004) . These co-crystal structures suggest that a bromine substitution on position 7 would be detrimental to the interaction of indirubins with their targets as will be described in detail elsewhere (in preparation). A general steric hindrance by the bromine is supported by the fact that IO substituted with a small atom such as fluorine is much more active toward kinases than when the position 7 is substituted with other halogens (Table 1) . This overall unfavorable position 7 substitution is confirmed by the kinase selectivity panel (Table 2) , which shows that, compared to IO, 5BIO and 6BIO, 7BIO interacts poorly with protein kinases. However, this panel only represents 85 out of 518 kinases and the possibility that 7BIO potently inhibits one or several unidentified kinases remains open. In addition, 7BIO may bind to its targets in an orientation which is widely different from that of IO and 6BIO in CDKs and GSK-3.
Indirubins appear to induce different forms of cell death according to their substitutions. We reported previously that a transient exposure to IO triggered a necrotic type cell death in nocodazole-synchronized HBL100 cells (Damiens et al., 2001) . In contrast, IO apparently triggered apoptotic type cell death in MCF-7 cells . Various 5-substituted indirubins also induce apoptosis as evidenced by poly-(ADP-ribose) polymerase cleavage (Nam et al., 2005) . This apoptosis appears to be correlated with downregulation of survival factors such as survivin and Mcl-1. Induction of apoptosis has also been recently described for 5-nitro-indirubin-3 0 -oxime (Lee et al., 2005) .
Six arguments demonstrate that 7BIO induces cell death by a mechanism distinct from apoptosis: (1) a morphological study of dying cells shows that 7BIO induces the appearance of large pycnotic nuclei, without classical features of apoptosis such as nuclear fragmentation and secondary necrosis ( (Figure 11) ; (6) neither Bcl-2 nor Bc-XL overexpression significantly reduce the level of 7BIO-induced cell death (Figure 12b) .
What is the nature of 7BIO-induced cell death? Besides apoptosis, a number of caspase-independent cell death mechanisms have been described (reviews in Jaattela, 2004; Broker et al, 2005) . One such pathway is autophagy, a cellular process involved both in cell survival and in cell death which requires the family of Atg genes (review in Baehecke, 2005) . Whether such a pathway is involved in 7BIO-induced cell death is currently under investigation. Recently, a new caspaseindependent cell death process, necroptosis, was described that displays some of the characteristics of necrosis and activation of autophagy . We are currently investigating this pathway as a potential mechanism of action of 7BIO. Interestingly, it is inhibited by a family of substituted indoles called necrostatins . Substituents (methyl, halogen) at position 7 on necrostatin result in increased inhibitory activity (Teng et al., 2005) . Given their partial structure similarity, it is tempting to speculate that necrostatins and 7BIO might share a target which they affect in opposite directions. Another description of caspase-independent cell death implies the generation of reactive oxygen species (ROS) (Chipuk and Green, 2005) . Although preliminary experiments suggest that 7BIO does not induce the generation of ROS in vitro (unpublished), we are still exploring this possible mechanism of action of 7BIO. Electron microscopy examination of 7BIO-treated cells reveals that 7BIO induces a prominent disruption of endoplasmic reticulum without markedly affecting the nucleus (data not shown), suggesting that 7BIO acts as a potent reticulum stress inducer.
Indirubins interact with and activate AhR leading to the upregulation of cytochrome P450 and p27 HL-60 Figure 13 7-Bromoindirubin-3 0 -oxime (7BIO) induces caspaseindependent cell death in four additional cell lines. IMR-5, IMR-32, HL-60 and Jurkat cells were challenged with increasing concentrations of 7BIO for 24 h and cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium procedure (left). Every point is the mean7s.e. of three independent experiments with six independent measurements per experiment. The same cell lines were subjected for 24 h to treatments with staurosporine (1 mM), 5-bromoindirubin-3 0 -oxime (25 mM), 7BIO (25 mM) or left untreated (U) and the activation of effector caspases (DEVDase activity in arbitrary fluorescent units) was measured (right). Bar value is the mean7s.e. of six independent determinations.
Antitumor activity of 7-bromoindirubin-3 0 -oxime J Ribas et al (Adachi et al., 2001; Spink et al., 2003; Knockaert et al., 2004; Sugihara et al., 2004) . 7-Bromoindirubin-3 0 -oxime clearly activates AhR as observed in an in vitro luciferase reporter system (unpublished), and confirmed by the AhR-dependent expression of p27
Kip1 and G1 arrest (Figure 4) . However, three pieces of evidence suggest that AhR is not involved in the cell death process induced by 7BIO: (1) 7BIO triggers cell death equally well in AhRÀ/À and AhR þ / þ cells; (2) neuroblastoma SH-SY5Y cells express very little if any AhR (unpublished); (3) Me7BIO, which is as potent as 7BIO in activating AhR, does not induce cell death.
7-Bromoindirubin-3 0 -oxime inhibits Aurora C and FLT-3 (Table 2 and unpublished data). Yet Me7BIO, which is as potent as 7BIO at inhibiting both kinases, does not trigger cell death (Figure 2b ). 7-Bromoindirubin-3 0 -oxime-induced cell death is therefore unlikely to be a direct consequence of inhibition of these two kinases. We also believe that 7BIO action does not involve the downregulation of STAT3 tyrosine phosphorylation and its subsequent inactivation as has been suggested for other indirubins (Nam et al., 2005) (Figure 11 ).
Although it is too early to speculate on the potential clinical use of 7-substituted indirubins, this new family of indirubins opens a promising research area. Firstly, these molecules seem to interact with much less kinases than previously described indirubins and thus appear to be more selective ( Table 2) . Identification of the molecular targets of 7BIO and 7-substituted indirubins obviously constitutes a high priority. We plan to tackle this using affinity chromatography on immobilized 7BIO as described for other kinase inhibitors (Bach et al., 2006) . Secondly, numerous cancer cells are characterized by the development of various mechanisms of resistance to apoptosis (for instance overexpression of the Bcl-2 and Bcl-XL oncogenic proteins). Such tumor cells thus constitute putative targets for 7-substituted indirubins such as 7BIO, which induce cell death through a non-apoptotic pathway and in a Bcl2/Bcl-XL-insensitive way. Such indirubins might thus allow the killing of tumor cells resistant to conventional anticancer drugs.
Materials and methods
Chemistry
General chemistry experimental procedures All chemicals were purchased from Aldrich Chemical Co. NMR spectra were recorded on Bruker DRX 400; chemical shifts are expressed in ppm downfield from TMS. The C NMR experiments were performed using standard Bruker microprograms. Chemical ionizaton-tandem-mass spectrometry (CI-MS) spectra were determined on a Finnigan GCQ Plus ion-trap mass spectrometer using CH 4 as the CI ionization reagent. Column chomatographies were conducted using flash silica gel 60 Merck (40-63 mm), with an overpressure of 300 mbar. All the compounds gave satisfactory combustion analyses (C, H, N, within 70.4% of calculated values).
Indirubin synthesis general procedures 5-Bromoindirubin (5BI), 7-bromoindirubin (7BI), 7-chloroindirubin (7CI), 7-iodoindirubin (7II), 7-fluoroindirubin (7FI) and 7-bromo-1-methylindirubin (Me7BI) were prepared from 5-bromoisatin, 7-bromoisatin, 7-chloroisatin, 7-iodoisatin, 7-fluoroisatin, 7-bromo-1-methylisatin, respectively, and 3-acetoxyindol. The synthesis of the corresponding indirubins and isatins will be described in details elsewhere (Polychronopoulos et al., 2004, in preparation) .
5-Bromoindirubin-3 0 -oxime, 7BIO,7CIO, 7IIO 7FIO and Me7BIO were prepared from the corresponding indirubins and hydroxylamine hydrochloride. Indirubin-3 0 -oxime and 6BIO were synthesized as described previously (Leclerc et al., 2001; Polychronopoulos et al., 2004) .
General procedure for the preparation of the indirubin-oximes 5BIO, 7BIO, 7CIO, 7IIO, 7FIO and Me7BIO The appropriate indirubin derivative 5BI, 7BI, 7CI, 7II, 7FI or Me7BI (1 mmol) was dissolved in pyridine (10 ml). With magnetic stirring, hydroxylamine hydrochloride (10 eq) was added and the mixture was heated under reflux (1201C) for 1.5 h. Then the solvent was evaporated under reduced pressure and the residue was washed with water and cyclohexane to afford quantitatively the corresponding 3 0 -oxime. -P]-ATP was obtained from Amersham, Buckinghamshire, UK. The GS-1 peptide (YRRAAVPPSPSLSRHSSPHQSpEDEEE) was synthesized by the Peptide Synthesis Unit, Institute of Biomolecular Sciences (University of Southampton, Southampton, UK).
Buffers
Homogenization buffer: 60 mM b-glycerophosphate, 15 mM pnitrophenylphosphate, 25 mM MOPS (pH 7.2), 15 mM EGTA, 15 mM MgCl 2 , 1 mM DTT, 1 mM sodium vanadate, 1 mM NaF, 1 mM phenylphosphate, 10 mg leupeptin/ml, 10 mg aprotinin/ ml, 10 mg soybean trypsin inhibitor/ml and 100 mM benzamidine.
Buffer A: 10 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 mg heparin/ml.
Buffer C: homogenization buffer but 5 mM EGTA, no NaF and no protease inhibitors.
Kinase preparations and assays Kinase activities were assayed in buffer A or C, at 301C, at a final ATP concentration of 15 mM. Blank values were subtracted and activities calculated as picomoles of phosphate incorporated for a 10-min incubation. The activities are usually expressed in % of the maximal activity, that is, in the absence of inhibitors. Controls were performed with appropriate dilutions of dimethylsulfoxide.
CDK1/cyclin B was extracted in homogenization buffer from M-phase starfish (Marthasterias glacialis) oocytes and purified by affinity chromatography on p9 CKShs1 -sepharose beads, from which it was eluted by free p9
CKShs1 as described previously (Meijer et al., 1997) . The kinase activity was assayed in buffer C, with 1 mg histone H1/ml, in the presence of 15 mM [g 33 -P] ATP (3000 Ci/mmol; 10 mCi/ml) in a final volume of 30 ml. After 30 min incubation at 301C, 25 ml aliquots of supernatant were spotted onto 2.5 Â 3 cm pieces of Whatman P81 phosphocellulose paper, and, 20 s later, the filters were washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/litre of water. The wet filters were counted in the presence of 1 ml ACS (Amersham) scintillation fluid.
CDK5/p25: This was reconstituted by mixing equal amounts of recombinant mammalian CDK5 and p25 expressed in Escherichia coli as glutathione-S-transferase (GST) fusion proteins and purified by affinity chomatography on glutathione-agarose (vectors kindly provided by Dr JH Wang) (p25 is a truncated version of p35, the 35 kDa CDK5 activator). Its activity was assayed with histone H1 in buffer C as described for CDK1/cyclin B.
Glycogen synthase kinase-3a/b: This was purified from porcine brain by affinity chomatography on immobilized axin . It was assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 ml 4 mM GS-1 peptide substrate, in buffer A, in the presence of 15 mM [g 33 -P] ATP (3000 Ci/mmol; 10 mCi/ml) in a final volume of 30 ml. After 30 min incubation at 301C, 25 ml aliquots of supernatant were processed as described above.
ProQinase protein kinase assays: All protein kinases were expressed in Sf9 insect cells as human recombinant GST-fusion proteins or His-tagged proteins by means of the baculovirus expression system. Kinases were purified by affinity chomatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen, Courtabeuf, France). The purity and identity of each kinase was checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)/Coomassie staining and by Western blot analysis. A proprietary protein kinase assay (33 PanQinase s Activity Assay) was used to assay the recombinant enzymes. All kinase assays were performed in 96-well Flash Platest from Perkin Elmer/NEN (Boston, MA, USA) in a 50ml reaction volume using a BeckmanCoulter/Sagian robotic system. The reaction cocktail was pipetted in four steps in the following order: (i) 20 ml of assay buffer, (ii) 5 ml of ATP solution (in H 2 O), (iii) 5 ml of test compound (in 10% DMSO) and (iv) 10 ml of substrate/10 ml of enzyme solution (premixed). The assays for all kinases (except for protein kinase C (PKC), see below) contained 60 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-NaOH, pH 7.5, 3 mM MgCl 2 , 3mM MnCl 2 , 3mM Na-orthovanadate, KIP1 and p53 were purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Monoclonal antibody against cytochrome c and rabbit polyclonal against Bcl-XL were provided by BD Biosciences, San Diego, CA, USA. AntiBcl-2 (clone 124) monoclonal antibody was purchased from Dako, Glostrup, Denmark. Anti-PhosphoTyr705-STAT3 and anti-STAT3 antibodies were from Cell Signalling, Denver, CO, USA. The antitubulin antibody was from Sigma.
Cell lines and culture conditions The mouse 5L hepatoma cell line (AhR þ / þ ) and BP8 (an AhRÀ/À subclone) were kindly provided by Dr M Goe¨ttlicher (Forschungszentrum Karlsruhe, Institute of Genetics, Karlsruhe, Germany). They were cultured in Dulbecco's modified Eagle's medium (DMEM) (Biowhittaker, Verviers, Belgium) supplemented with 2 mM Lglutamine (Eurobio), 10% fetal calf serum (FCS), and gentamycin (Gibco BRL, Paisley, Scotland, UK) at 371C in an atmosphere of 7% CO 2 . Indirubin or TCDD treatments were performed on 50-60% confluent cultures at the indicated time and concentrations. Control experiments were carried out using appropriate dilutions of DMSO.
SH-SY5Y, IMR-5 and IMR-32 human neuroblastoma cell lines were grown in DMEM medium from (Biowhittaker) plus 2 mM L-glutamine from Eurobio (Courtaboeuf, France) or DMEM already supplemented with 2 mM L-glutamine (Invitrogen, Barcelona, Spain), plus antibiotics and a 10% volume of FCS (Invitrogen, Cergy Pontoise, France or Barcelona, Spain). SH-SY5Y cell lines permanently transfected with pcDNA3/Bcl-2, pcDNA3/Bcl-XL and empty pcDNA3 vectors were grown like their untransfected counterparts. However, Geneticin (G-418) selection was maintained in the growing cultures before the terminal experiments (Ribas and Boix, 2004) . In order to induce differentiation, SH-SY5Y cells were cultured on collagen coated plates and treated with 10 mM RA for 5 days.
HL-60 and Jurkat cells were grown in Rosewell Park Memorial Institute media 1640 medium with 10% FCS and antibiotics from Invitrogen (Barcelona, Spain).
HCT116 human adenocarcinoma cell line was kindly provided by Dr Vogelstein (The Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, MD, USA). HCT116 cells were cultured in McCoy's 5A (Biowhittaker) supplemented with antibiotics and 10% FCS. General culture conditions were an atmosphere of 5% CO 2 and a temperature of 371C. Culture dishes and other plastic disposable tools were supplied by Corning (Corning, NY, USA). Indirubin treatments were performed on exponentially growing cultures at the indicated time and concentrations. Control experiments were carried also using appropriate dilutions of DMSO.
MDA-MB-231 cells (derived from hormone-independent breast cancer) were cultured in DMEM supplemented with 10% FCS. For experiments, these cells were seeded in 24-well boxes or in 35 mm Petri dishes at appropriate densities (4.10 4 cells per well for cell growth experiments; 10 5 cells per dish for cell cycle analysis) and exposed to indirubins as indicated.
Cell proliferation and cell cycle analysis Propidium iodide staining was performed as follows. First, SL, BP8 or MDA-MB-231 cells were harvested from the culture plates and washed once with phosphate-buffered saline, pH 7.4. Second, 1-2 Â 10 5 cells were incubated for 15 min in 25 mg/ml PI, 10 mg/ ml RNase A and 0.1% Triton X-100. Flow cytometry readings were obtained by an EPICS s XL2 unit from Coulter (Beckman, CA, USA). Data were processed by means of WinMDI (a free software from Joe Trotter) in order to obtain monoparametric DNA histograms. Finally, these histograms were analysed with the Multi-Cycle software.
Cell death and cell viability assessments Cell death characterization based on nuclear morphology was assessed by double staining with 0.05 mg/ml Bisbenzimide and 25 mg/ml PI. Cell viability was determined by means of the MTS method. Both procedures have been previously described in detail (Ribas and Boix, 2004) . For evaluation of DNA laddering, cell DNA was extracted and electrophoresed in 1.5% agarose gels to evidence the internucleosomal fragmentation typical of apoptosis.
Caspase assay The measurement of caspase activity is based on determining the fluorescence released from the AcDEVDafc synthetic substrate after its direct addition to the culture medium, detergent lysis, and incubation at 371C. This method is devised to be applied to 96-multiwell plates. It allows kinetic determinations of caspase activation and the characterization of multiple drugs simultaneously (Ribas et al., 2005) .
Electrophoresis and Western blotting Whole-cell extracts were obtained in buffer containing 100 mM Tris/HCl pH. 6.8, 1 mM EDTA, 2% SDS. Following heat denaturation for 3 min, proteins were separated by 10% SDS-PAGE (0.7 mm thick gels) (p27 Kip1 ) or by 10% NuPAGE precast Bis-Tris polyacrylamide mini gel electrophoresis system (Invitrogen) with MOPS SDS (p53, p21
Cip1 , actin) or MES SDS (cytochrome c) running buffer depending on protein size. Proteins were transferred to 0.45 mM nitrocellulose filters (Schleicher and Schuell). These were blocked with 5% low-fat milk in Trisbuffered saline-Tween-20, incubated for 1 h with antibodies (anti-p27 KIP1 : 1:1000; anti-actin: 1:1000; anti-Bcl-2, 1:2000; anti-Bcl-XL, 1:5000; anti-tubulin, 1:4000; anti-STAT3: 1:1000) or overnight at 41C (anti-p53: 1:1000; p21
Cip1
: 1:1000; cytochrome c: 1:1000; anti-actin: 1:5000 (STAT3 experiment); anti-phosphoTyr705-STAT3: 1:1000) and analysed by enhanced chemiluminescence (Amersham).
To study expression of p53 and p21 Cip1 , cells were lysed for 30 min at 41C in radioimmunoprecipition assay buffer (150 mM NaCl, 1% NP40, 0.5% deoxycholate, 0.1% SDS and 50 mM Tris-HCl pH 8.0) supplemented with a protease inhibitor cocktail (Roche). After centrifugation (12 000 g for 10 min), the protein concentration was determined in the supernatants by the Bradford protein assay (Bio-Rad, Marnes-la-Coquette, France). To study cytochrome c release from mitochondria, a 0.05% digitonin cytosolic extraction was performed (Ribas and Boix, 2004) .
In the STAT3 study, cells were lysed in 30 mM HEPES (pH 7.5), 10 mM NaCl, 5 mM MgCl 2 , 25 mM NaF, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 2 mM sodium orthovanadate, 6.4 mg/ml p-nitrophenylphosphate and protease inhibitor cocktail (Roche). Total proteins (73 mg) was resolved on 10% NuPAGE with MOPS SDS running buffer.
Abbreviations
AhR, aryl hydrocarbon receptor; ARNT, aryl hydrocarbon receptor nuclear translocator; BIO, bromoindirubin-3 0 -oxime; CDK, cyclin-dependent kinase; FCS, fetal calf serum; FLT-3, FMS-like tyrosine kinase 3; GSK-3, glycogen synthase kinase-3; IFNa, interferon a; IO, indirubin-3 0 -oxime; LDH, lactate dehydrogenase; MeBIO, 1-methyl-bromoindirubin-3 0 -oxime; MeIO, 1-methyl-indirubin-3 0 -oxime; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H -tetrazolium; RA, retinoic acid; ROS, reactive oxygen species; STS, staurosporine; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.
